Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAG | P20916 | 4/20 | 0.38 |
| ▸ | CD22 | P20273 | 5/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16348268 | 0.88 | L3MBTL1 (0.45) | L3MBTL1MAGCD22DDB1CRBN | |
| SCHEMBL17546165 | 0.88 | L3MBTL1 (0.45) | L3MBTL1MAGCD22DDB1CRBN | |
| SCHEMBL28320235 | 0.88 | L3MBTL1 (0.45) | L3MBTL1MAGCD22DDB1CRBN | |
| SCHEMBL10084278 | 0.88 | L3MBTL1 (0.45) | L3MBTL1MAGCD22DDB1CRBN | |
| SCHEMBL20305857 | 0.87 | L3MBTL1 (0.40) | L3MBTL1MAGCD22ALDH1A1HTR2C | |
| SCHEMBL14946228 | 0.85 | MAG (0.52) | L3MBTL1MAGCD22 | |
| SCHEMBL30481193 | 0.85 | MAG (0.52) | L3MBTL1MAGCD22 | |
| SCHEMBL31500844 | 0.85 | MAG (0.52) | L3MBTL1MAGCD22 | |
| SCHEMBL27977966 | 0.85 | MAG (0.52) | L3MBTL1MAGCD22 | |
| SCHEMBL25702221 | 0.85 | MAG (0.52) | L3MBTL1MAGCD22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297846-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-8840926-B2 | Sialic acid analogs | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130122094-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297846-A1 | SIALIC ACID ANALOGS | NEU1, NEU2, NEU3 | L3MBTL1 1717/4885MAG 768/4885CD22 108/4885 |
| US-20130122094-A1 | SIALIC ACID ANALOGS | NEU1, NEU2, NEU3 | L3MBTL1 1717/4885MAG 768/4885CD22 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.